A single center study on the clinical features and treatment of infectious mononucleosis in children
10.3760/cma.j.issn.1003-9279.2018.01.003
- VernacularTitle: 儿童传染性单核细胞增多症临床特征及治疗的单中心研究
- Author:
Wenxian OUYANG
1
;
Hui ZHANG
1
;
Jing LIU
2
;
Yanfang TAN
1
;
Sijing YU
2
;
Lian TANG
1
;
Tao JIANG
1
;
Zhen KANG
1
;
Juan YAO
1
;
Yonggui ZHU
1
;
Shuangjie LI
1
Author Information
1. Hepatology Center, Hunan Children’s Hospital, Changsha 410011, China
2. Department of Infectious Diseases
- Publication Type:Journal Article
- Keywords:
Children;
Infectious mononucleosis;
Clinical features;
Antiviral therapy
- From:
Chinese Journal of Experimental and Clinical Virology
2018;32(1):12-16
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features of children with infectious mononucleosis (IM), to compare the difference of therapeutic effects between general treatment to antiviral therapy for IM.
Methods:This prospective study analyzed the clinical data and laboratory test results of 201 cases with IM in our hospital from January 1, 2016 to December 31, 2016. The follow-up period was 6-12 months. The patients were divided into two groups according to the order of admission. The clinical symptoms and laboratory test results of the two groups were observed after hospitalization.
Results:Of the total of 201 patients, male to female is 1.72∶1; Age: 8 months to 13 years 6 months (average 4.8±2.8 years), The disease frequently occurred in summer and autumn, accounted for 64.18%.The major clinical manifestations was fever (97.51%), angina (79.10%), enlarged of lymph node(68.66%), eyelid swelling (67.16%), hepatomegaly (53.73%) and splenomegaly (46.77%). There was no statistical difference in duration of fever, improved angina time, lymph nodes(liver, spleen) enlargement recovery time, heterotypic lymphocytes normalization time, lymphocyte function normalization time.There was significant difference in reducing the serum/plasma or total blood EBV-DNA in the short term between antiviral group and general treatment group (P<0.01), but for the long-term reduction of EBV-DNA, there was no significant difference (P>0.05). The low affinity EBV-CA-IgG was converted to high affinity EBV-CA-IgG in 89.41% of patients after 3 months and in 98.68% of patients after 6 months. With the recovery of the disease, the positive rate of EBV-CA-IgM and EBV-EA-IgG decreased. But the positive rate of EBV-NA-IgG increased. Serum/plasma EBV-DNA was completely overcast after 3 months, but after 12 months, the patient’s total blood EBV-DNA positive rate was still 71.11%.
Conclusions:In general IM patients, there was no significant difference between antiviral therapy and general treatment, so antiviral therapy is not generally recommended. EBV DNA in the whole blood of patients with IM will continue to be positive more than 6-12 months, indicating that to observe changes of IM should not use whole blood samples for EBV DNA testing.
